Ophthalmologic Manifestations of Behcet Disease Follow-up

  • Author: Mounir Bashour, MD, CM, FRCS(C), PhD, FACS; Chief Editor: Hampton Roy Sr, MD   more...
 
Updated: Apr 4, 2012
 

Further Outpatient Care

  • Patients with Behçet disease should receive follow-up care as needed.
Next

Prognosis

  • Spontaneous remissions and relapses characterize the natural history of ocular Behçet disease.
  • Visual prognosis in countries (ie, Japan, Turkey) that have the highest prevalence of Behçet disease is poor.
    • In Japan and Turkey, more than 50% of cases result in legal blindness within 4 years of onset.
    • The prevalence of blindness in Behçet disease patients in North America is 25%.
    • Possible explanation for this discrepancy includes genetic heterogeneity, with the occurrence of more severe disease in the Mideast and the Far East.
Previous
 
Contributor Information and Disclosures
Author

Mounir Bashour, MD, CM, FRCS(C), PhD, FACS  Assistant Professor of Ophthalmology, McGill University; Clinical Assistant Professor of Ophthalmology, Sherbrooke University; Medical Director, Cornea Laser and Lasik MD

Mounir Bashour, MD, CM, FRCS(C), PhD, FACS is a member of the following medical societies: American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, American College of International Physicians, American College of Surgeons, American Medical Association, American Society of Cataract and Refractive Surgery, American Society of Mechanical Engineers, American Society of Ophthalmic Plastic and Reconstructive Surgery, Biomedical Engineering Society, Canadian Medical Association, Canadian Ophthalmological Society, Contact Lens Association of Ophthalmologists, International College of Surgeons US Section, Ontario Medical Association, Quebec Medical Association, and Royal College of Physicians and Surgeons of Canada

Disclosure: Nothing to disclose.

Specialty Editor Board

John D Sheppard Jr, MD, MMSc  Professor of Ophthalmology, Microbiology and Molecular Biology, Clinical Director, Thomas R Lee Center for Ocular Pharmacology, Ophthalmology Residency Research Program Director, Eastern Virginia Medical School; President, Virginia Eye Consultants

John D Sheppard Jr, MD, MMSc is a member of the following medical societies: American Academy of Ophthalmology, American Society for Microbiology, American Society of Cataract and Refractive Surgery, American Uveitis Society, and Association for Research in Vision and Ophthalmology

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

R Christopher Walton, MD  Professor, Director of Uveitis and Ocular Inflammatory Disease Service, Department of Ophthalmology, Assistant Dean for Graduate Medical Education, University of Tennessee College of Medicine; Consulting Staff, Regional Medical Center, Memphis Veterans Affairs Medical Center, St Jude Children's Research Hospital

R Christopher Walton, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Healthcare Executives, American Uveitis Society, Association for Research in Vision and Ophthalmology, and Retina Society

Disclosure: Nothing to disclose.

Lance L Brown, OD, MD  Ophthalmologist, Affiliated With Freeman Hospital and St John's Hospital, Regional Eye Center, Joplin, Missouri

Disclosure: Nothing to disclose.

Chief Editor

Hampton Roy Sr, MD  Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences

Hampton Roy Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, and Pan-American Association of Ophthalmology

Disclosure: Nothing to disclose.

References

  1. Davatchi F. Diagnosis/Classification Criteria for Behcet's Disease. Patholog Res Int. 2012;2012:607921. [Medline]. [Full Text].

  2. Hatemi G, Yazici H. Behçet's syndrome and micro-organisms. Best Pract Res Clin Rheumatol. Jun 2011;25(3):389-406. [Medline].

  3. Houman MH, Hamzaoui K. Promising new therapies for Behcet's disease. Eur J Intern Med. May 2006;17(3):163-9. [Medline].

  4. Torres RM, Yanez B, Herreras JM, Calonge M. [Ocular Behcet disease. Retrospective study]. Arch Soc Esp Oftalmol. Dec 2004;79(12):599-603. [Medline].

  5. Pipitone N, Boiardi L, Olivieri I, et al. Clinical manifestations of Behcet's disease in 137 Italian patients: results of a multicenter study. Clin Exp Rheumatol. 2004;22(6 Suppl 36):S46-51. [Medline].

  6. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M. Uveitis in Behcet disease: an analysis of 880 patients. Am J Ophthalmol. Sep 2004;138(3):373-80. [Medline].

  7. Kaya TI. Genetics of Behçet's Disease. Patholog Res Int. 2012;2012:912589. [Medline]. [Full Text].

  8. Dursun A, Durakbasi-Dursun HG, Dursun R, Baris S, Akduman L. Angiotensin-converting enzyme gene and endothelial nitric oxide synthase gene polymorphisms in Behçet's disease with or without ocular involvement. Inflamm Res. Mar 3 2009;[Medline].

  9. Maldini C, Lavalley MP, Cheminant M, de Menthon M, Mahr A. Relationships of HLA-B51 or B5 genotype with Behcet's disease clinical characteristics: systematic review and meta-analyses of observational studies. Rheumatology (Oxford). Jan 11 2012;[Medline].

  10. Borhani Haghighi A, Pourmand R, Nikseresht AR. Neuro-Behçet disease. A review. Neurologist. Mar 2005;11(2):80-9. [Medline].

  11. Yurdakul S, Mat C, Tuzun Y, et al. A double-blind trial of colchicine in Behçet's syndrome. Arthritis Rheum. Nov 2001;44(11):2686-92. [Medline].

  12. Evereklioglu C. Ocular Behçet disease: current therapeutic approaches. Curr Opin Ophthalmol. Nov 2011;22(6):508-16. [Medline].

  13. Cantini F, Niccoli L, Nannini C, Kaloudi O, Cassarà E, Susini M, et al. Efficacy of infliximab in refractory Behçet's disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients. Biologics. 2012;6:5-12. [Medline]. [Full Text].

  14. Baldassano VF Jr. Ocular manifestations of rheumatic diseases. Curr Opin Ophthalmol. Dec 1998;9(6):85-8. [Medline].

  15. Borruat FX. Neuro-ophthalmologic manifestations of rheumatologic and associated disorders. Curr Opin Ophthalmol. Dec 1996;7(6):10-8. [Medline].

  16. Bredvik BK, Trocme SD. Ocular manifestations of immunological and rheumatological inflammatory disorders. Curr Opin Ophthalmol. Dec 1996;7(6):91-5. [Medline].

  17. Dinowitz K, Aldave AJ, Lisse JR, Trocme SD. Ocular manifestations of immunologic and rheumatologic inflammatory disorders. Curr Opin Ophthalmol. Dec 1994;5(6):91-8. [Medline].

  18. Eldem B, Onur C, Ozen S. Clinical features of pediatric Behcet's disease. J Pediatr Ophthalmol Strabismus. May-Jun 1998;35(3):159-61. [Medline].

  19. George RK, Chan CC, Whitcup SM, Nussenblatt RB. Ocular immunopathology of Behcet's disease. Surv Ophthalmol. Sep-Oct 1997;42(2):157-62. [Medline].

  20. Sakane T, Takeno M, Suzuki N, Inaba G. Behcet's disease. N Engl J Med. Oct 21 1999;341(17):1284-91. [Medline].

  21. Yazici H, Barnes CG. Practical treatment recommendations for pharmacotherapy of Behcet's syndrome. Drugs. Nov 1991;42(5):796-804. [Medline].

 
Previous
Next
 
Treatment modalities currently used in Behçet disease according to clinical symptoms.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.